Belantamab mafodotin

DREAMM-7 trial interim analysis shows Blenrep plus BorDex significantly reduces death risk in relapsed/refractory multiple myeloma compared to daratumumab plus BorDex. Full data to be presented at 2024 ASH Annual Meeting, with results shared with health authorities for regulatory filings.

The DREAMM-8 trial compared belantamab mafodotin-blmf, pomalidomide, and dexamethasone (BPd) to pomalidomide, bortezomib, and dexamethasone (PVd) in multiple myeloma patients. BPd showed superior progression-free survival (PFS) not reached vs 12.7 months (HR, 0.52; 95% CI, 0.37-0.73; 2-sided P < .001), deeper responses, and higher complete response rates (40% vs 16%).

Antibody drug conjugates (ADCs) are a transformative class in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is expected to surpass $50B by 2030, driven by over 500 ADCs in clinical trials. Key players include Enhertu, Kadcyla, and Padcev, with significant sales in breast and lung cancers. The US and China lead the market, supported by robust R&D and regulatory environments.

The Cancer Antibody Drug Conjugates Market report highlights the transformative potential of ADCs in cancer treatment, with 16 approved products and sales exceeding $10B in 2023. The market is projected to surpass $50B by 2030, driven by ongoing clinical trials and increased R&D efforts. Key players include Padcev, Kadcyla, and Enhertu, with significant development activity in lung and breast cancer. The market is led by the US and China, with major pharmaceutical companies driving innovation.

GSK's RSV vaccine Arexvy sales dropped 72% in Q3 due to narrower US recommendations and COVID-19 vaccination prioritization. Pfizer's Abrysvo sales declined only 5%, suggesting Pfizer's ascendency in the RSV vaccine market. GSK's overall vaccine sales fell 15%, leading to a revised forecast of low-single-digit percentage gains. Despite this, GSK's overall revenues increased 2% to $8 billion, supported by HIV drugs and specialty medicines.

GSK delivered Q3 sales and core operating profit growth, with strong specialty medicines offsetting lower vaccine sales. The pipeline strengthened with 11 positive phase III trials and 5 major product launches planned for next year. Zantac litigation was resolved, aligning with 2024 guidance and bolstering confidence in 2026 and 2031 outlooks. Forward-looking statements are subject to risks and uncertainties.

GSK Q3 2024 results: £8.0 billion sales (-2% AER, +2% CER), driven by Specialty Medicines (+19%) offsetting Vaccines (-15%). Core operating profit +5%, Core EPS +5%. R&D progress includes EU approval for Arexvy, HIV PrEP effectiveness, and oncology breakthroughs. 2024 guidance confirmed: 7-9% turnover growth, 11-13% Core operating profit growth, 10-12% Core EPS growth, excluding COVID-19 solutions.

FDA approves Cologuard Plus for colorectal cancer screening; advancements in breast cancer care include genomic testing; HBI0101 CAR T-cell therapy shows promise in multiple myeloma; neoadjuvant nivolumab plus chemotherapy approved for NSCLC; Belantamab mafodotin-blmf combo demonstrates efficacy in relapsed/refractory multiple myeloma.